文献速递胸部肿瘤放疗乳腺癌放疗姑息放疗与转移瘤

现代癌症放射治疗试验中的心血管事件报告

Cardiovascular Event Reporting in Modern Cancer Radiation Therapy Trials.
PubMed 文献 · Adv Radiat Oncol · 2021-12-29

该研究分析了2000至2019年间108项胸部放疗的前瞻性试验,共59,070例乳腺癌、肺癌、淋巴瘤、间皮瘤或食管癌患者。中位随访48个月,报告468例主要不良心脏事件(MACE),50.0%的试验未报告MACE,37.0%未报告任何心血管事件,试验报告的MACE发生率低于相似非试验人群。

要点

  • 在108项胸部放疗试验中,50.0%未报告MACE,37.0%未报告任何心血管事件。
  • 试验报告MACE的总体加权发生率为每10万人年376例,低于非试验人群的每10万人年1408例(RR 0.27,P < .001)。
  • 中位随访48个月报告468例MACE,干预组307例 vs 对照组144例(RR 1.96,P < .001)。

核心结论

  • 在现代以胸部放疗为基础的临床试验中,报告的心血管疾病发生率低于预期人群发生率。

研究设计与样本

  • 从10种高影响力放射治疗、肿瘤学和医学期刊中筛选2000至2019年间入组乳腺癌、肺癌、淋巴瘤、间皮瘤或食管癌并接受胸部放疗的后期阶段试验,共纳入108项试验、59,070例患者(平均年龄58.0 ± 10.2岁,46.0%为女性),可随访人年为273,587人年。

主要发现

  • 中位随访48个月,共报告468例MACE(包括96例心力衰竭、75例急性冠脉综合征、1例血运重建、94例心律失常、28例卒中、20例心血管死亡),干预组307例 vs 对照组144例(RR 1.96,P < .001)。
  • 50.0%的试验未报告MACE,37.0%的试验未报告任何心血管疾病。
  • 试验总体加权MACE发生率为每10万人年376例,相似非试验患者为每10万人年1408例(RR 0.27,P < .001)。
  • 未发现与心血管疾病报告相关的放疗因素。

关键数值与推荐

  • 主要结局为治疗组间报告主要不良心脏事件(MACE),定义为新发心肌梗死、心力衰竭、冠状动脉血运重建、心律失常、卒中或心血管死亡。
  • 次要结局为报告任何心血管疾病事件。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Cardiovascular disease (CVD) is the leading cause of morbidity and mortality in cancer survivors, particularly after chest radiation therapy (RT). However, the extent to which CVD events are consistently reported in contemporary prospective trials is unknown. METHODS AND MATERIALS: From 10 high-impact RT, oncology, and medicine journals, we identified all latter phase trials from 2000 to 2019 enrolling patients with breast, lung, lymphoma, mesothelioma, or esophageal cancer wherein chest-RT was delivered. The primary outcome was the report of major adverse cardiac events (MACEs), defined as incident myocardial infarction, heart failure, coronary revascularization, arrhythmia, stroke, or CVD death across treatment arms. The secondary outcome was the report of any CVD event. Multivariable regression was used to identify factors associated with CVD reporting. Pooled annualized incidence rates of MACEs across RT trials were compared with contemporary population rates using relative risks (RRs). RESULTS: The 108 trials that met criteria enrolled 59,070 patients (mean age, 58.0 ± 10.2 years; 46.0% female), with 273,587 person-years of available follow-up. During a median follow-up of 48 months, 468 MACEs were reported (including 96 heart failures, 75 acute coronary syndrome, 1 revascularization, 94 arrhythmias, 28 strokes, and 20 CVD deaths; 307 occurred in the intervention arms vs 144 in the control arms; RR, 1.96; P < .001). Altogether, 50.0% of trials did not report MACEs, and 37.0% did not report any CVD. The overall weighted-trial incidence was 376 events per 100,000 person-years compared with 1408 events per 100,000 person-years in similar nontrial patients (RR, 0.27; P < .001). There were no RT factors associated with CVD reporting. CONCLUSION: In contemporary chest RT-based clinical trials, reported CVD rates were lower than expected population rates.

来源:Adv Radiat Oncol,查看原文。版权归原作者所有。

引用

  1. Prasad RN, McIntyre M, Guha A, et al. Cardiovascular Event Reporting in Modern Cancer Radiation Therapy Trials. Adv Radiat Oncol. 2021. PMID: 35198835. doi:10.1016/j.adro.2021.100888

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。